Drug Hypersensitivity
Conditions
Keywords
Hypersensitivity, Syndrome, Tegeline
Brief summary
Efficacy and tolerance of Tegeline® treatment in hypersensitivity syndrome. Immunological study of the T cell index phenotype and functionality in hypersensitivity syndrome.
Interventions
DRUGTegeline®
2g/kg in IV on 2days 2g/kg in IV on 4days for patients with renal insufficiency or 65 years old.
Sponsors
University Hospital, Rouen
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Age \>= 18 * Cutaneous and/or mucous eruption * Polyadenopathy * Body temperature \> 38°C * Hematology disorders : Hypereosinophily \> 1.5 G/l, lymphocytosis \> 5G/l, atypical blood lymphocytes * Consent obtained from patient
Exclusion criteria
* Age \< 18 * No consent obtained from patient * IgV allergy * Dress with very sérious visceral attack and vital diagnostic (sharp cardiac insufficiency, sharp respiratory insufficiency, hepatic insufficiency, sharp renal insufficiency) * Oral therapy or immunosuppressive therapy (Methotrexate, cyclosporine, cyclophosphamide, etc.) * IgA deficiency, * MCI \>=35 * Sharp renal insufficiency before Dress with creatinaemia \< 60 ml/min (Cockroft)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| express healing of visceral attacks, healing of polyadenopathy and body temperature, biological abnormal values normalisation, express healing of cutaneous and mucous diseases immunological study of the T cell index phenotype | 1 year |
Countries
France
Outcome results
None listed